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Background: Schizophrenia is a debilitating mental disorder that presents impairments in neurocognition and social
cognition. Several studies have suggested that the etiology of schizophrenia can be partly explained by oxidative stress.
However, our knowledge about the implications of oxidative stress on illness-related cognitive deficits is still far from
being clear. The aim of this work was to study the role of oxidative stress molecules on social cognition and
neurocognition in patients with schizophrenia.
Methods: We assessed the peripheral levels of several molecules associated with oxidative stress, namely nitric
oxide (NO), malondialdehyde (MDA), glutathione (GSH), homocysteine, superoxide dismutase (SOD) and neurotrophin
4/5 (NT4/5), in forty–one patients with schizophrenia and forty-three healthy participants. A battery of tests to measure
neurocognition and social cognition was also administered to the schizophrenia group.
Results: We found that the schizophrenia group presented substantially higher levels of oxidative stress than the
control group, as revealed by elevated quantities of the pro-oxidants NO and MDA, and decreased levels of the
antioxidants GSH, SOD and NT4/5. Interestingly, the levels of NT4/5, which have been shown to have antioxidant
effects, correlated with executive functioning, as measured by two distinct tests (WCST and TMT). However, social
cognition and symptom severity were not found to be associated with oxidative stress.
Conclusions: We propose a protective role of NT4/5 against oxidative stress, which appears to have a potentially
beneficial impact on neurocognition in schizophrenia.
Keywords: Neurotrophin 4, Neurotrophin 5, Glutathione, Malondialdehyde, Nitric oxide, Superoxide dismutase,
Reactive oxygen species, Theory of mind, Emotion recognition, Executive functioning, Working memoryBackground
Schizophrenia is a severely debilitating mental disorder
that is characterized by different neurodevelopmental
and behavioral abnormalities, with deficits in perception,
emotion processing and social functioning [1,2]. Mul-
tiple genetic and environmental risk factors for schizo-
phrenia have been identified, including drug and alcohol
abuse, prenatal infections and malnutrition [3-5]. Des-
pite the heterogeneity of risk factors, the underlying* Correspondence: crxgonza@gmail.com
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article, unless otherwise stated.biological mechanism linking these processes could be
associated with oxidative stress [6-8]. Oxidative stress is
induced by excessive generation of reactive oxygen spe-
cies (ROS) or a lack of appropriate removal, which can
consequently cause neural cell damage [9]. Oxidative
stress has been found to be prevalent in many psychi-
atric disorders [10] and though it may not be the only
cause of schizophrenia, it has been suggested to play a
crucial role in the course of the illness [11,12].
Most studies that have assessed oxidative stress in
schizophrenia populations point to an increase in toxic
damage due to both increased pro-oxidants and de-
creased antioxidants [13]. In schizophrenia, numerous
reports have found oxidative stress in cerebrospinal fluided Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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cingulate cortex in post-mortem studies [15], and in per-
ipheral tissues and plasma of schizophrenia patients
[16-18]. More specifically, several authors have reported
elevated levels of the oxidative stress indicators malon-
dialdehyde (MDA) and nitric oxide (NO), along with
lower levels of the antioxidant molecule glutathione
(GSH) in schizophrenia patients as compared to healthy
controls [19-21]. However, some controversy still exists
regarding the levels of antioxidant enzymatic activity
evaluated by superoxide dismutase (SOD), catalase (CAT)
and glutathione peroxidase (GSH-Px) [11,17,22-26].
In addition to common oxidative stress biomarkers,
some endogenous neurotrophic factors such as neuro-
trophin 4/5 (NT4/5) have recently been shown to be im-
plicated in the up-regulation of antioxidants in neural
cells [27]. While the effects of brain-derived neuro-
trophic factor (BDNF) on oxidative stress and its rela-
tionship to disease has been extensively studied [27], few
reports have investigated how NT4/5 affects neuro-
psychiatric disorders. Walz and colleagues reported in-
creased NT4/5 in the serum of patients with bipolar
disorder and thus argued that the increase in NT4/5 oc-
curs as a compensatory mechanism to deal with oxida-
tive stress in dopaminergic neurons [28]. On the other
hand, decreased antioxidant defense, including reduced
levels of NT4/5, has been found in the brains of patients
with Alzheimer’s disease [29-31]. However, the relation-
ship between NT4/5 and schizophrenia remains unclear.
At the behavioral level, social functioning in schizo-
phrenia patients is modulated by several factors, includ-
ing social cognition and neurocognition [32]. Social
cognition denotes the ability to process, assimilate and
respond to social stimuli, and can be categorized into
several domains that work at different levels; from basic
low-level emotion perception, to theory of mind (i.e. to
attribute and understand the mental states of others,
such as beliefs and intentions) up to appropriate behav-
ioral responses [33]. Additionally, social cognitive deficits
have been linked to symptom severity in schizophrenia,
and are negatively associated with quality of life and social
functioning [34]. Neurocognition, on the other hand, is
defined by the cognitive skills necessary to carry out psy-
chological processes, and can be categorized into inde-
pendent but interrelated subdomains, including executive
function, working memory and attention. Intact neurocog-
nition is essential for social functioning [35,36].
Several studies suggest that oxidative stress has detri-
mental effects on socio- and neurocognitive abilities in
schizophrenia. For instance, Pavlovic and colleagues have
suggested that oxidative stress is increased in patients
with greater positive symptoms [21]. Equally interesting,
another study showed in post-mortem studies that
schizophrenia patients had higher oxidative stress in theanterior cingulate cortex (ACC), a brain region involved
in emotion and social processing [15]. Most notably,
Martinez-Cengotitabengoa and colleagues were the first
to investigate the potential relationship between the
levels of oxidative stress and neurocognition in schizo-
phrenia, and found a significant correlation between
GSH and executive function [37]. Together, these studies
point toward a general effect of oxidative stress on social
cognition and neurocognition. Despite the extensive
studies focusing on oxidative stress indicators as possible
biomarkers, there are no reports that have systematically
explored the relationship between oxidative stress, social
cognition and neurocognition in schizophrenia.
The present study aimed to first quantify and compare
markers of oxidative stress in a schizophrenia sample
and a healthy control group, and then to closely examine
the relationship between oxidative stress parameters and
a variety of social and cognitive domains in schizophre-
nia. We were mostly interested in the link between the
levels of several biomarkers (namely SOD, GSH, MDA,
homocysteine, NO and NT4/5) and theory of mind
(ToM), emotion processing, working memory and ex-
ecutive functioning. We hypothesized that (1) oxidative
stress is higher in the schizophrenia patients and (2) is
related to deficits in social cognition (i.e. emotion process-




Fifty clinically stable schizophrenia patients and fifty
age-matched healthy controls without psychiatric dis-
orders, as evaluated by structured clinical interview
for DSM-IV (SCID), were recruited from Celal Bayar
University, Psychiatry Department, Psychosis Unit. The
schizophrenia group was diagnosed according to the
DSM-4TR by clinically trained and experienced psychia-
trists. The inclusion criteria were as follows: age between
18–60, no evidence of neurological deficits, no drug or
alcohol abuse and no hospitalization in the six months
before the recruitment phase of the study. After the re-
cruitment, all patients and controls were screened for
chronic physical illness (history of hypertension, diabetes,
hyperlipidemia, peripheral vascular disease, coagulopathy
and the presence of hematological, renal, or hepatic
disease) from their previous medical records. Due to the
potential confounding effects on peripheral markers of
oxidative stress, participants who had evidence of chronic
physical illness were excluded, according to consultation
with an internal medicine specialist. Notably, none of the
patients or controls were receiving anti-inflammatory
medications or vitamin supplements on a regular basis,
as evaluated by the sociodemographic questionnaires. This
screening procedure was done before data collection, and
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and forty-three healthy controls were included in the final
sample for the study. The socio-demographical and clinical
features of the sample are summarized in Table 1. Chlor-
promazine equivalents were calculated for all patients
in order to control for medication effects [38,39]. As a
note, all patients were treated with second and third
generation antipsychotics (14.6% olanzapine, 14.6% que-
tiapine, 34% risperidone, 22% aripiprazole, 22.2% cloza-
pine, 9.8% others (sertindole, paliperidone, ziprasidone)).
The study was approved by the Institutional Review Board
(IRB) at the Celal Bayar University and was performed in
accordance with the Declaration of Helsinki. All partici-
pants were evaluated for their capacity to give informed
consent and provided written informed consent after all
procedures were fully explained.
Symptomatology (PANSS)
Symptom severity was measured with the Positive and
Negative Syndrome Scale (PANSS [40]), a 30-item semi-
structured interview designed to assess three symptom
categories associated with schizophrenia: positive symp-
toms (e.g., hallucinations and delusions), negative symp-
toms (e.g., avolition and anhedonia), and general
symptoms (e.g., hostility, and depression). One trained andTable 1 Demographic, clinical and cognitive variables
Schizophrenia
Percentage (Count) Mean SD
Sex Males 46% (19)
Females 54% (22)
Age (years) 32.32 9.08
Education (years) 11.06 3
Nr. of Hospitalization 1.5 1.99
Duration of illness (years) 9.42 6.29
CPZ equivalents (mg) 457.55 280.94
PANSS Positive subscale 11.96 4.67
PANSS Negative subscale 17.91 6.15
PANSS General subscale 28.39 8.72
PANSS Total 58.26 17.82
Memory Quotient 74,05 33.48
WCST Correct Responses 64.97 21.49
WCST Completed Groups 2.44 2.13
RVLT (learning score) 5.31 2.08
TMT- A (seconds) 56.60 29.52
TMT- B (seconds) 130.09 71.96
Hinting (total correct) 12.11 3.37
FRT (total correct) 11.19 2.65
PANSS: Positive and Negative Syndrome Scale; WCST: Wisconsin card sorting test; RVcalibrated rater assigned a score from 1 to 7 for each item,
with higher scores indicating more severe psychopath-
ology. The patient group mean scores for the PANSS were
11.96 ± 4.67 for positive symptoms, 17.91 ± 6.15 for nega-
tive symptoms, 28.39 ± 8.72 for general symptoms, and
58.26 ± 17.82 for the total score.
Cognitive assessment
Cognitive assessment (i.e. neurocognition and social
cognition) was only administered to the schizophrenia
group, and not to the healthy controls, on the same day as
the blood sample collection.
Neurocognitive assessment
The Turkish versions of two neuropsychological tests
were used to evaluate intelligence, memory and execu-
tive functioning. The tests were administered and scored
by a trained psychiatrist (Z.C.) who was blind to the
clinical data of the patients. More specifically, working
memory performance was assessed with the Wechsler
Memory Scale-III (WMS-III; [41]). Age-corrected indi-
ces of the Memory Quotient were accepted as a measure
of working memory performance. Verbal learning was
measured by the Rey Auditory Verbal Learning Test
[42]. The learning score was calculated from the totalControls
Percentage (Count) Mean SD Statistics
42% (17) X2(2,N = 84) = .39, p = .53
58% (26)
29.74 8 t(82) = 1.38, p = .17
11.14 2.12 t(82) = .142, p = .57
LT: Rey verbal learning test; TMT: Trail making test; FRT: Face Recognition Test.
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sured with the Wisconsin Card Sorting Test-CV64
(WCST; [43]), where number of correct answers, num-
ber of perseverative errors and number of completed
groups were included in the analyses. Visuo-spatial
orientation was measured with the number of correct re-
sponses in the Judgment of Line Orientation Test [44].
Visual search, scanning, speed of processing and mental
flexibility was measured by the total amount of time
(seconds) to complete the Trail Making Test A and B
(TMT A and B) [45].
Social cognitive assessment
The Turkish versions of three widely used social cogni-
tion measures were used to evaluate emotion perception
and theory of mind skills. The performance tests were
administered by a trained psychiatrist and then patients
were rated by a psychiatrist and a psychologist together
to improve accuracy and to rule out potential interrater
differences. More specifically, emotion perception was
measured using the Face Emotion Identification Task
(FEIT) and the Face Emotion Discrimination Task (FEDT)
[46] using six basic facial emotion expressions (happy,
angry, afraid, sad, surprised, and ashamed) presented on
screen. Cognitive theory of mind (ToM) abilities were
measured with the Hinting task [47], which consists of ten
brief written vignettes describing social scenarios that the
participant is asked to interpret. The total number of cor-
rect responses ranges from 0 to 20, with higher scores
indicating better performance.
Assessment of oxidative stress molecules
Patients were asked to refrain from eating or doing
physical exercise 8 hours before the beginning of the
sample collection. Blood samples (10 mL) were collected
from the participants at admission time (9:00 a.m. to
10:00 a.m.) and were placed in three tubes: one with-
out anticoagulant for serum and two with 0.1 mL of
0.47 mol/L EDTA (anticoagulant), one of which was
utilized for plasma and one for whole blood analysis.
Plasma and serum were obtained by centrifugation
and together with the whole blood sample were kept
at −80°C until analysis. Neurotrophin-4/5 (NT4/5),
superoxide dismutase (SOD), nitric oxide (NO), and
homocysteine were analyzed from serum, malondial-
dehyde (MDA) from plasma and total glutathione (GSH)
from whole blood samples.
SOD activity was determined using enzyme-linked im-
munosorbent assay (ELISA), which measures the three
types of SOD (Cu/Zn, Mn, and FeSOD), according
to the manufacturer’s instructions (Cayman Chemical
Company, Michigan, USA). The working principle of
the kit consists of the utilization of tetrazolium salt to
detect the dismutation of superoxide radicals producedby xanthine oxidase and hypoxanthine. One unit of SOD
corresponds to the amount of enzyme required for 50%
of the dismutation of superoxide radical. Absorbance
was read at 450 nm.
Serum NO levels were assayed by the Griess method.
The Griess diazotization reaction detects nitrite created
by the spontaneous oxidation of NO. Samples are incu-
bated in an acidic environment with sulfanilamide and
N-1-naphthyl ethylene diamine (NED), which convert
the nitrites into a purple product. Absorbance was read
at 550 nm.
NT4/5 levels from serum samples were measured by
ELISA according to the manufacturer’s protocol (Cusabio
Biotech, Wuhan, China). We deposited the samples on
microplates coated with antibodies specific for NT4/5.
After washing the sample and leaving NT4/5 bound to
the immobile antibody, a biotin-conjugated antibody was
added to the microplates, followed by another wash and
the addition of avidin-conjugated horseradish peroxidase
(HRP). After washing, a substrate was added and color
developed, which we measured spectrophotometrically at
450 nm.
Serum homocysteine levels were determined by chemilu-
minescence automatic immunoassay analyzer as indicated
by the manufacturer’s protocol (Immulite-2000, Diagnostic
Products Corporation, LA, USA). A chemiluminescent
substrate was added to a reaction tube where homocyst-
eine was bound to a coated bead. The signal is generated
in proportion to the bound enzyme.
GSH and MDA levels were determined by HPLC ac-
cording to the manufacturer’s instructions (ImmuChrom
GmbH Schimadzu Prominence, Kyoto, Japan). Analytical
RP-HPLC separations were performed using a Shimadzu
Prominence HPLC system equipped with a Shimadzu
SPD-20A detector (Kyoto, Japan).
Statistical analyses
The assumption criteria for conducting parametric stat-
istical analyses were checked for in the preliminary step.
The distribution of the outcome and dependent variables
was checked with the Shapiro-Wilk test. Non-parametric
tests were utilized where normality was violated. The
patient and control group differences in sociodemo-
graphics were tested with independent t-tests and chi-
square. Group differences in oxidative stress molecules
were tested using Mann Whitney U tests. A Bonferroni-
corrected critical p value was calculated based on the
total number of group comparisons to adjust the level of
significance for multiple comparisons (critical P = .009).
Lastly, Pearson correlation analyses were performed be-
tween the social and neurocognitive measures and the
oxidative stress molecules in the schizophrenia patients.
Statistical significance was set to p <0.05. All statistical
analyses were performed with SPSS version 20.
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Group comparison of the levels of oxidative stress
related molecules
We found significant group differences in all oxidative
stress-related molecules except for plasma homocysteine
levels (F (1,83) = .002, p = 0.965). Accordingly, higher
levels of MDA and NO were observed in the schizophre-
nia group. In addition, significantly lower levels of GSH,
SOD and NT4/5 were found in the schizophrenia pa-
tients. The group differences and the statistical values
are summarized in Table 2.
Correlation analyses
SOD levels were significantly associated with GSH levels
(r = 0.349; p = < .05). Although not significant, consistent
findings were observed between pro-oxidant and anti-
oxidant molecules such that antioxidants showed nega-
tive associations with pro-oxidants (Table 3). In regards
to the association of social cognition and neurocognition
with these oxidative stress markers, we found a signifi-
cant correlation between NT4 levels and executive func-
tioning, as shown by the number of correct responses
(r = .474, p < .001) and completed groups (r = −.399,
p < .001) in the WCST (Figure 1). In addition, a negative
correlation (r = −0.333, p = .047) was observed between
the total time to complete the TMT-A and plasma NT4
levels in the schizophrenia patients. However, social cog-
nition measures were not correlated with any of the
oxidative stress indicators. We also did not find any
correlations between the oxidative stress markers and
medication, duration of illness nor symptom severity
measured with the PANSS. The correlation analyses are
summarized in Table 3.
Discussion
The present study sought to compare the levels of oxida-
tive stress between schizophrenia patients and healthy
controls, and to examine the relationship between oxida-
tive stress parameters (including NT4/5), social cogni-
tion and neurocognition in the patient group. We foundTable 2 Group means for markers of oxidative stress and resu
Schizophrenia Cont
Mean SD Mean
Homocystein (μmol/L) 16.52 9.73 16.62
GSH (μmol/L) 539.46 206.58 986.2
MDA (μmol/L) 1.19 0.17 0.98
NO (μmol/L) 92.15 37.55 65.23
SOD (U/ml) 0.26 0.15 0.39
NT4/5 (ng/ml) 5.2 2.88 6.56
GSH: total glutathione; MDA: malondialdehyde; NO: nitric oxide; SOD: superoxide dihigher levels of oxidative stress in schizophrenia patients
as compared to controls, as well as a correlation between
NT4/5 and neurocognition but not social cognition in
the clinical group. This highlights the relationship be-
tween biological markers and cognition in neuropsychi-
atric disorders.
Numerous studies have previously assessed the levels
of oxidative stress biomarkers in schizophrenia patients,
and most have pointed towards an imbalance in the
reduction-oxidation (redox) system due to increased
pro-oxidants and reduced antioxidants [12,20-22]. In
agreement with previous findings, we show that the
schizophrenia group exhibits significantly higher levels
of MDA and NO [20,23,48], as well as lower quantities
of SOD and GSH [20,22,23,49], both of which support
the hypothesis that these compounds contribute to
the imbalance between the generation and removal of
ROS. Compatible with these findings, supplementa-
tion with essential polyunsaturated fatty acids (which
are decreased due to lipid peroxidation), Vitamin C
and Vitamin E (two antioxidants) improves symptom-
atology, general psychopathology and quality of life in
schizophrenia patients [50].
On the other hand, our findings on the homocysteine
levels between groups contradicts previous studies show-
ing an increase of homocysteine in the schizophrenia
group [51,52]. This contrast in outcomes could be due
to differences in the age and duration of illness of the
participants used in other samples, as well as the poten-
tial variability caused by the different methods used to
assess the levels of this compound [51,52]. Alternatively,
our results may also suggest a non-specific influence of
homocysteine on the neurodevelopment of schizophrenia.
In addition, we observed a significant correlation be-
tween the levels of GSH and SOD, which may indicate a
potential connection between these two antioxidants.
Moreover, we found a trend that suggests a positive rela-
tionship between GSH and NT4/5, whereas NO appears
to be inversely related to NT4/5, although these cor-
relations did not reach statistical significance. This islts of group comparisons
rols Statistics
(Mann Whitney U)
SD U (df) Z p
12.22 845.5(82) .27 0.775
3 179.68 105.0(82) 6.95 <.001
0.22 359.0(82) 4.68 <.001
39.53 509.0(82) 3.33 0.001
0.16 177.5(82) 6.30 <.001
2.79 620.5(82) 2.34 0.02
smutase; NT4/5: neurotrophin 4/5.
Table 3 Correlations between oxidative stress markers and measures of social and neurocognition in schizophrenia patients
Homocystein GSH MDA NO SOD NT4/5
Homocystein -
GSH .250 -
MDA .111 .175 -
NO -.121 -.047 -.189 -
SOD -.098 .346* -.179 .038 -
NT4/5 .233 .213 .098 -.240 -.011 -
Hinting Task -.205 -.063 .198 -.030 -.064 .043
Face Recognition Test .310 -.152 .102 .132 -.228 .083
RVLT .032 -.171 .071 -.201 -.001 .092
WCST Correct response .260 .001 -.071 .120 -.051 .474**
WCST Completed groups .195 .171 .171 -.131 -.218 .399*
MQ -.097 -.054 .216 -.062 .041 .269
TMT-A -.158 -.135 -.147 .150 .044 -.333*
TMT-B -.251 -.119 -.117 .130 .048 -.272
GSH: total glutathione; MDA: malondialdehyde; NO: nitric oxide; SOD: superoxide dismutase; NT4/5: neurotrophin 4/5; WCST: Wisconsin Card Sorting Test;
MQ: Memory Quotient; RVLT Rey verbal learning test; MQ: memory quotient; TMT: Trail Making Test. *p = 0.05, **p = 0.01. Values in table represent
correlation coefficients.
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and oxidative stress, while GSH and NT4/5 are protect-
ive against oxidative damage [27,53-58]. In support of
this relationship, a study showed that adding NT4/5
to cultured midbrain neural cells prevented them from
dying due to NO-dependent oxidative damage [59]. It is
plausible that a similar mechanism occurs in humans;
nonetheless, further studies are needed to assess this
possibility.
One main finding of this work is the presence of de-
creased NT4/5 levels in the schizophrenia group. Some
authors have found that, although NT4/5 has protective
effects in oxidative stress-induced apoptosis in vitro,Figure 1 Scatterplot between NT4/5 and executive function
(WCST correct responses).NT4/5 can potentiate unprogrammed cell death [56,57,60].
Accordingly, it has been previously suggested that apop-
totic vulnerability is a characteristic of schizophrenia,
even though neuronal apoptosis does not seem to occur
more often than in healthy controls [61]. Other studies
have found that apoptotic signaling molecules were
higher in a schizophrenia group, but there was no dif-
ference in the apoptotic trigger molecules (i.e. caspase 3)
when compared to a healthy group [61,62]. They there-
fore proposed that apoptotic vulnerability is increased in
schizophrenia and presumably leads to local synaptic loss
but not cell death. Taken together, our results may then
indirectly suggest that schizophrenia patients are more
vulnerable to apoptotic cell death, and that NT4/5 is a
protective regulator of such cellular damage caused by
oxidative stress. The mechanism underlying this process
could involve the up-regulation of antioxidants by NT4/5
[27]. While no studies have so far investigated the rela-
tionship between NT4/5 and oxidative stress in schizo-
phrenia, Walz and colleagues found increased levels of
NT4/5 in bipolar patients, which the authors justified as
being a compensatory mechanism against oxidative dam-
age in dopaminergic neurons [28]. It is likely that, due to
the lower NT4/5 levels, this compensation mechanism is
not possible in schizophrenia. Future research may profit
from focusing on how NT4/5 impacts on cognition.
Interestingly, we found a positive correlation between
NT4/5 and executive functioning as assessed by the
WCST, as well as a positive correlation between NT4/5
and visual attention and task switching as tested by the
TMT-A, which implies that NT4/5 has some residual
beneficial effects on neurocognition in this disease. It is
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creasing oxidative status and thus protects neuronal
synapses, which in turn facilitates better functioning. Al-
though not widely investigated, this is in line with stud-
ies suggesting a relationship between oxidative stress
and neurocognition in a variety of other clinical popula-
tions [63-66]. Nevertheless, there is only one study in
the literature that examined the relationship between
oxidative damage and neurocognition in schizophrenia.
In this study, Martinez-Cengotitabengoa and colleagues
found a positive correlation between GSH and executive
functioning, and a negative correlation between nitrites
(the final product of NO) and executive functioning in
first episode psychosis patients (FEP) [37]. However, the
results from our study did not confirm these previous
findings. It is possible that methodological differences
and the duration of illness, as the study from Martinez-
Cengotitabengoa et al. used FEPs, led to these divergent
results. In fact, a recent meta-analysis has suggested that
a number of oxidative stress parameters, including ni-
trites, are dependent on the illness state, i.e. the periph-
eral amounts depend on whether the patients are in
their first episode of psychosis, acutely relapsed inpa-
tients or stable outpatients [67]. Further work is required
to assess the progression of, and the relationship be-
tween, these and other biomarkers and neurocognition
in schizophrenia.
Contrary to our hypothesis, we did not find a relation-
ship between oxidative stress biomarkers and social cog-
nition. Although neurocognitive deficits in schizophrenia
explain some variance of social cognitive deficits, a sub-
stantial number of studies have demonstrated the inde-
pendent role of social cognition in symptom severity,
social functioning and quality of life in schizophrenia
patients (reviewed in [33]). Furthermore, many studies
have successfully identified a separate function for differ-
ent subdomains of social cognition [68]. However, the
distinction between the domains of social cognition and
the associated brain areas is less clear when compared to
similar work on neurocognition. For instance, neuroim-
aging data on neurocognition suggests a specific task-
dependent activation of brain regions, such as in the
dorsolateral pre-frontal cortex (DLPFC), while perform-
ing a working memory task [69]. Taken together with
postmortem studies in schizophrenia [70,71], it is plaus-
ible to argue that the damage caused by oxidative stress
to specific brain regions may negatively influence neuro-
cognitive faculties.
In contrast, activity in a substantially broader network
involving the cingulate cortex, temporoparietal junction
(TPJ), inferior parietal cortex (IPC), DLPFC and ventro-
medial pre-frontal cortex (VMPFC) has emerged for
emotion recognition and theory of mind-related social
cognitive tasks [72]. Thus, a similar proposal might notbe as legitimate for social cognition, especially as previ-
ous studies have shown that neural compensation for
damage to the brain network related to social cognitive
tasks is possible. For instance, Newsome et al. demon-
strated that a group of adolescents who had traumatic
brain injuries (TBI) recruit alternative neural pathways
to compensate for theory of mind impairments related
to the affected areas by TBI, and hence had similar pro-
cessing speeds as healthy controls [73]. This evidence
may provide a clue to the interpretation of the result
that we did not find any correlation between social cog-
nition and oxidative stress, even though the NT4/5
levels that were negatively associated with NO predicted
some variance in executive functioning. Lastly, it should
also be noted that our work involved the most com-
monly studied subdomains of social cognition, namely
emotion recognition and theory of mind. However, other
social cognitive domains such as attributional style and
metacognition should also be taken into consideration in
future studies examining the effects of oxidative stress
on cognitive domains.
This study presents some limitations. Firstly, the rela-
tionship between neurocognition and social cognition
and oxidative stress markers were not evaluated in the
healthy group. Therefore, our findings are more specific
to a schizophrenia population and it is not clear whether
or not the relationship between oxidative stress and neu-
rocognition is specific to patients with this disorder. Sec-
ondly, although we carefully controlled for the effects of
chronic physical illness on oxidative stress molecules,
nearly all of the schizophrenia patients (87,8%; N = 36)
were smokers, which was not the case for the controls,
and therefore the effects of smoking on oxidative stress
molecules [74] cannot be ruled out. We also did not
consider body mass index (BMI), which may affect oxi-
dative stress status [75]. Finally, this work was carried
out utilizing peripheral markers of oxidative stress and it
is thus possible that the amount of these molecules does
not accurately reflect central levels.
Conclusion
In conclusion, our study confirms that the detrimental
effects of oxidative damage in schizophrenia are due to a
combination of reduced protection and augmented oxi-
dative insults. However, oxidative parameters should not
be used as biomarkers for schizophrenia given that these
are not disease specific, although they might have poten-
tial as markers to determine cognitive faculties. Interest-
ingly, our results bring new insight into the relationship
between NT4/5 and neurocognition in schizophrenia.
This study provides further clues to the underlying role
of pathological differences in oxidative stress and how
this translates to deficits at the behavioral level, with
NT4/5 being of particular interest here.
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